CHICAGO — Maura Dickler, MD, vice president of late-phase oncology development at Eli Lilly, spoke with HemOnc Today about key data presented at ASCO Annual Meeting.
Dickler highlighted two ASCO presentations in the thoracic oncology space.
One is the randomized phase 3 RELAY study — which evaluated erlotinib (Tarceva; Genentech, Astellas) in combination with ramucirumab (Cyramza, Eli Lilly) or placebo for previously untreated patients with EGFR mutation-positive metastatic non-small cell lung cancer.
The other presentation provided an update from the KEYNOTE-189 study, which assessed pembrolizumab (Keytruda, Merck) plus chemotherapy with pemetrexed (Alimta, Eli Lilly) and platinum vs. placebo plus chemotherapy for patients with metastatic nonsquamous NSCLC.
Dickler also discussed the randomized phase 3 ANNOUNCE trial, presented as part of ASCO’s plenary session.
The trial failed to confirm the OS benefit of adding olaratumab (Lartruvo, Eli Lilly) to standard doxorubicin for patients with advanced soft tissue sarcoma. These results appeared inconsistent with results of a phase 2 trial, which showed the combination improved PFS and OS.
Dickler also provided an overview of two recent acquisitions for Eli Lilly and key investigational agents in the company’s pipeline.
“We’re focused very much now on speed, as well as on developing drugs based on a rational tumor biology to ultimately deliver the best value to our patients with cancer,” Dickler said. – by Mark Leiser
Gadgee SM, et al. Abstract 9013. Presented at: ASCO Annual Meeting; May 31-June 4, 2019; Chicago.
Nakagawa K, et al. Abstract 9000. Presented at: ASCO Annual Meeting; May 31-June 4, 2019; Chicago.
Tap WD, et al. Abstract LBA3. Presented at: ASCO Annual Meeting; May 31-June 4, 2019; Chicago.